Related Experiment Video
Updated: Jun 18, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Decoding the Factor H-Related Proteins: Gatekeepers of Complement Dysregulation in AMD
Jiaqi Tang1, Nathalie Zgoda1, Simon J Clark1,2,3
1Institute for Ophthalmic Research, Department for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Factor H-related proteins (FHRPs) drive complement amplification, contributing to age-related macular degeneration (AMD). Targeting FHRPs may offer a novel therapeutic strategy for reducing AMD risk and blindness.
Area of Science:
- Ophthalmology
- Immunology
- Genetics
Background:
- Age-related macular degeneration (AMD) is a leading cause of blindness, affecting millions globally.
- Complement system overactivation, due to diminished regulatory capacity, contributes to AMD pathogenesis.
- Factor H (FH) and Factor H-like protein 1 (FHL1) are key complement regulators, but their loss of control is not the sole driver of AMD.
Purpose of the Study:
- To explore the emerging role of factor H-related proteins (FHRPs) in AMD.
- To investigate the association between FHRPs and AMD risk.
- To examine potential therapeutic strategies targeting FHRPs for AMD.
Main Methods:
- Review of current literature on FHRPs and their role in complement regulation.
- Analysis of genetic evidence linking FHRP gene deletions to AMD protection.
- Examination of studies correlating circulating FHRP levels with ocular deposition and AMD.
Main Results:
- FHRPs have an emerging role in driving complement amplification.
- FHRP gene deletions are associated with protection against AMD.
- Elevated FHRP levels correlate with their deposition in the eye, the site of AMD pathology.
Conclusions:
- FHRPs represent a significant factor in AMD pathogenesis through complement amplification.
- Targeting FHRPs presents a promising novel therapeutic avenue for AMD.
- Further research into FHRP mechanisms can lead to effective AMD risk reduction strategies.
Related Concept Videos
Complement System
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Hepatic Encephalopathy
Ligand-Gated Ion Channel Receptor: Gating Mechanism

